Abstract
Disrupted kynurenine pathway (KP) metabolism has been implicated in the progression of neurodegenerative disease, psychiatric disorders and cancer. Modulation of enzyme activity along this pathway may therefore offer potential new therapeutic strategies for these conditions. Considering their prominent positions in the KP, the enzymes indoleamine 2,3-dioxygenase, kynurenine 3-monooxygenase and kynurenine aminotransferase, appear the most attractive targets. Already, increasing interest in this pathway has led to the identification of a number of potent and selective enzyme inhibitors with promising pre-clinical data and the elucidation of several enzyme crystal structures provides scope to rationalize the molecular mechanisms of inhibitor activity. The field seems poised to yield one or more inhibitors that should find clinical utility.
Keywords: Kynurenine pathway, neurodegeneration, cancer, indoleamine 2, 3-dioxygenase, kynurenine 3- monooxygenase, enzyme inhibitors.
Current Medicinal Chemistry
Title:Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Volume: 24 Issue: 23
Author(s): Kelly R. Jacobs, Gloria Castellano-Gonzalez , Gilles J. Guillemin *David B. Lovejoy *
Affiliation:
- Department of Biomedical Research, Faculty of Medicine and Health Science, Macquarie University, 2 Technology Place, Sydney,Australia
Keywords: Kynurenine pathway, neurodegeneration, cancer, indoleamine 2, 3-dioxygenase, kynurenine 3- monooxygenase, enzyme inhibitors.
Abstract: Disrupted kynurenine pathway (KP) metabolism has been implicated in the progression of neurodegenerative disease, psychiatric disorders and cancer. Modulation of enzyme activity along this pathway may therefore offer potential new therapeutic strategies for these conditions. Considering their prominent positions in the KP, the enzymes indoleamine 2,3-dioxygenase, kynurenine 3-monooxygenase and kynurenine aminotransferase, appear the most attractive targets. Already, increasing interest in this pathway has led to the identification of a number of potent and selective enzyme inhibitors with promising pre-clinical data and the elucidation of several enzyme crystal structures provides scope to rationalize the molecular mechanisms of inhibitor activity. The field seems poised to yield one or more inhibitors that should find clinical utility.
Export Options
About this article
Cite this article as:
Jacobs R. Kelly, Castellano-Gonzalez Gloria , Guillemin J. Gilles*, Lovejoy B. David*, Major Developments in the Design of Inhibitors along the Kynurenine Pathway, Current Medicinal Chemistry 2017; 24(23) . https://dx.doi.org/10.2174/0929867324666170502123114
DOI https://dx.doi.org/10.2174/0929867324666170502123114 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Janus Face of Cathelicidin in Tumorigenesis
Current Medicinal Chemistry Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Application of Stimuli-responsive Nanocarriers for Targeted Drug Delivery
Current Topics in Medicinal Chemistry Design of Telomerase Inhibitors for the Treatment of Cancer
Current Pharmaceutical Design Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy SUI-Current Medicinal Therapeutic Options
Current Women`s Health Reviews Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Fundamental Concepts of the Angiogenic Process
Current Molecular Medicine From Nanotechnology to Nanomedicine: Applications to Cancer Research
Current Molecular Medicine Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents
Current Medicinal Chemistry Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Natural and Synthetic Retinoids in Prostate Cancer
Current Pharmaceutical Design Immunology Behind Tumors: A Mini Review
Current Cancer Therapy Reviews Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies
Current Medicinal Chemistry Temporal Expression of miRNAs in Laser Capture Microdissected Palate Medial Edge Epithelium from Tgfβ3<sup>-/-</sup> Mouse Fetuses
MicroRNA Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Botulinum Toxin a in Prostate Disease: A Venom from Bench to Bed-Side
Current Drug Delivery